RCC BA85#21 Cell Line for Antigen-Specific Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating clear cell renal carcinoma (RCC) are inadequate, as RCC is highly resistant to traditional chemotherapy and radiotherapy, and there is a lack of effective immunotherapeutic approaches due to the difficulty in identifying and utilizing highly immunogenic renal tumor antigens for immune system activation.
Innovation Solution
A stable and immunogenic cell line, RCC BA85#21, derived from clear cell renal carcinoma, is used to activate the immune system by co-incubation with immune cells, enabling the identification of new tumor antigens and the development of antigen-specific immune responses for therapeutic and prophylactic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy and radiotherapy are used to treat clear cell renal carcinoma, then treatment is administered, but the tumor shows high resistance and poor therapeutic response
Solution Approach 1:
The patent introduces dendritic cells as intermediary vehicles that carry and present tumor antigens to T-lymphocytes. This mediator mechanism enables the immune system to recognize and attack tumor cells that are resistant to traditional chemotherapy and radiotherapy, resolving the contradiction between treatment administration and therapeutic response.
Solution Approach 2:
The patent replaces the mechanical/chemical attack mechanisms of traditional chemotherapy and radiotherapy with a biological immune-based mechanism. By using dendritic cells and T-lymphocytes to recognize and destroy tumor cells through antigen presentation and immune activation, the system substitutes conventional physical/chemical treatment with a targeted biological response that overcomes tumor resistance.
2Reliability
If dendritic cells are used to present tumor antigens, then immune response is activated, but the identification and selection of highly immunogenic antigens remains difficult
Solution Approach 1:
The patent extracts and isolates specific tumor antigens from clear cell renal carcinoma cell lines and uses them to train dendritic cells. By separating and identifying specific immunogenic antigens (such as those expressed on the cell surface or released upon cell lysis), the system simplifies the complex task of antigen identification and enables reliable immune response activation.
Solution Approach 2:
The patent uses stable renal tumor cell lines as reproducible models to study and identify tumor antigens. These cell lines serve as copies or representations of the actual tumor, allowing researchers to systematically characterize antigen expression patterns and identify immunogenic targets in a controlled laboratory setting before applying the knowledge to patient treatment.
3Ease of manufacture
If stable renal tumor cell lines are isolated for vaccine preparation, then tumor antigens can be identified, but immunogenicity remains variable and insufficient
Solution Approach 1:
The patent modifies the characteristics of tumor cell lines through selective pressure and culture conditions to enhance their immunogenicity. By changing parameters such as cell passage number, culture medium composition, and stress conditions, the system increases the expression and presentation of tumor antigens on the cell surface, thereby improving the reliability of immune response activation while maintaining ease of cell line isolation and maintenance.
Data Source
AI summary
The present invention relates to a renal carcinoma cell line capable of activating the immune system in an antigen-specific manner. According to a further aspect, the invention also includes derivatives of the cell line that maintain said activation capacity. The invention also comprises a method for targeting and activating immune system cells against cells of clear cell renal carcinoma. Said method comprises the co-incubation of isolated immune system cells (dendritic cells, CD4+, CD8+ lymphocytes etc.) with cells of the RCC BA85#21 line in accordance with the invention in a suitable culture medium, for a time sufficient to obtain antigen specific cells.